Please assess the completion status of the following clinical trial:

Trial Title: A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females over 18 years of age~* 2-50 warts in the anogenital region.~* Female patients of child-bearing potential had to be willing to use a non-barrier method of contraception at entry and for the duration of the study.~* all patients had to be willing to use barrier protection for the duration of the study.~* All patients had to be able to comply with the requirements of the protocol and be likely to return for follow-up visits and had to be contactable for the duration of the study.~Exclusion Criteria:~* Patients with clinically relevant abnormal haematology or biochemistry results (determined from the sample taken at Visit 1).~* Patients who had used an active therapy for anogenital warts within 2 weeks of randomisation to study drug, i.e. Visit 2.~* Patients who had used any local supportive medication, including topical corticosteroids or beta-interferon, within 2 weeks of study entry.~* Patients who had used medication known to adversely affect their haematology profile, including local anaesthetics (benzocaine, lidocaine, etc), nitrofurantoin, sulphonylureas and sulphonamides within 2 weeks of study entry. \[Word 'adversely' added by Protocol Amendment 2, 7 May 2002.\]~* Patients with abnormal anogenital skin, such as eczema, or skin that had not healed following surgery (cryosurgery, laser ablation or similar).~* Patients who were known to have a concomitant sexually transmitted disease that inhibited accurate assessment of their warts.~* Patients who required treatment other than surgery or laser for internal warts.~* Male patients with intra-urethral warts \[deleted by Protocol Amendment 2, 7 May 2002\].~* Patients with diabetes (Type I or Type II diabetes).~* Patients who were known to be HIV-positive.~* Patients who were known to be immunosuppressed and/or using immunosuppressive therapies.~* Patients known to abuse alcohol and/or drugs or with a history of chronic alcohol or drug abuse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): placebo 0% nitrite cream and placebo 0% citric acid cream
- Topical NO Dose A (Type: ACTIVE_COMPARATOR): 3% sodium nitrite + 4.5% citric acid twice daily
- Topical NO Dose B (Type: ACTIVE_COMPARATOR): 6% sodium nitrite + 9% citric acid once daily
- Topical NO Dose C (Type: ACTIVE_COMPARATOR): 6% sodium nitrite + 9% citric acid twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).